GSK acquiring Affinivax and its next-generation pneumonia vaccine for $2.1 billion upfront

GSK has agreed to acquire Affinivax in a deal announced Tuesday, betting more than $3 billion that the eight-year-old startup’s technology can lead to a more effective pneumococcal vaccine than other currently available shots.